These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 17892993)

  • 1. Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease.
    Lev EI; Arikan ME; Vaduganathan M; Alviar CL; Tellez A; Mathuria N; Builes A; Granada JF; del Conde I; Kleiman NS
    Am Heart J; 2007 Oct; 154(4):694.e1-7. PubMed ID: 17892993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
    Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
    J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
    Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
    Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
    Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
    Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.
    Quinn MJ; Bhatt DL; Zidar F; Vivekananthan D; Chew DP; Ellis SG; Plow E; Topol EJ
    Am J Cardiol; 2004 Mar; 93(6):679-84. PubMed ID: 15019868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Hernández-Antolín R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Macaya C
    J Invasive Cardiol; 2004 Jun; 16(6):325-9. PubMed ID: 15156004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.
    Hochholzer W; Trenk D; Frundi D; Blanke P; Fischer B; Andris K; Bestehorn HP; Büttner HJ; Neumann FJ
    Circulation; 2005 May; 111(20):2560-4. PubMed ID: 15809367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
    Gurbel PA; Bliden KP; Hiatt BL; O'Connor CM
    Circulation; 2003 Jun; 107(23):2908-13. PubMed ID: 12796140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
    Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug.
    Labarthe B; Théroux P; Angioï M; Ghitescu M
    J Am Coll Cardiol; 2005 Aug; 46(4):638-45. PubMed ID: 16098428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.
    Steinhubl SR; Oh JJ; Oestreich JH; Ferraris S; Charnigo R; Akers WS
    Thromb Res; 2008; 121(4):527-34. PubMed ID: 17631948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacodynamics of clopidogrel.
    Thebault JJ; Kieffer G; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():3-8. PubMed ID: 10440415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
    Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
    Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.